“Peripheral Nerve Injuries Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Nerve Injuries Market.
The Peripheral Nerve Injuries Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Peripheral Nerve Injuries Pipeline Report:
Companies across the globe are diligently working toward developing novel Peripheral Nerve Injuries treatment therapies with a considerable amount of success over the years.
Peripheral Nerve Injuries companies working in the treatment market are Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others, are developing therapies for the Peripheral Nerve Injuries treatment
Emerging Peripheral Nerve Injuries therapies in the different phases of clinical trials are- Remplir, NTX-001, CAPNP, QUTENZA, and others are expected to have a significant impact on the Peripheral Nerve Injuries market in the coming years.
In September 2024, Neuraptive Therapeutics Inc., a prominent biopharmaceutical company dedicated to innovative treatments for peripheral nerve injuries, announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study were presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held from September 19-21 in Minneapolis, MN. The presentation, titled “Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial,” was recognized as a Top 10 Best Paper and delivered by Dr. David Brogan from Washington University. It showcased interim findings from the 24-week analysis of the NEUROFUSE study, which assesses the safety and efficacy of NTX-001 in patients with acute, single-transected upper extremity peripheral nerve injuries. NTX-001, a drug-device combination, aims to enhance the speed and sustainability of functional recovery when paired with standard surgical repair.
Peripheral Nerve Injuries Overview
Peripheral Nerve Injuries occur when the nerves outside the brain and spinal cord (the peripheral nervous system) are damaged. These injuries can result from trauma, compression, or medical conditions like diabetes. The peripheral nerves are responsible for transmitting signals between the central nervous system and the rest of the body, including muscles and skin. Damage to these nerves can lead to symptoms such as pain, weakness, numbness, or loss of function in the affected area. Treatment depends on the severity and type of injury and may include physical therapy, medications, or surgery.
Get a Free Sample PDF Report to know more about Peripheral Nerve Injuries Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/peripheral-nerve-injuries-pipeline-insight
Emerging Peripheral Nerve Injuries Drugs Under Different Phases of Clinical Development Include:
Remplir: Orthocell
NTX-001: Neuraptive Therapeutics
CAPNP: Samyang Biopharmaceuticals
QUTENZA: Astellas Pharma Inc
Peripheral Nerve Injuries Route of Administration
Peripheral Nerve Injuries pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Peripheral Nerve Injuries Molecule Type
Peripheral Nerve Injuries Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Peripheral Nerve Injuries Pipeline Therapeutics Assessment
Peripheral Nerve Injuries Assessment by Product Type
Peripheral Nerve Injuries By Stage and Product Type
Peripheral Nerve Injuries Assessment by Route of Administration
Peripheral Nerve Injuries By Stage and Route of Administration
Peripheral Nerve Injuries Assessment by Molecule Type
Peripheral Nerve Injuries by Stage and Molecule Type
DelveInsight’s Peripheral Nerve Injuries Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Peripheral Nerve Injuries product details are provided in the report. Download the Peripheral Nerve Injuries pipeline report to learn more about the emerging Peripheral Nerve Injuries therapies
Some of the key companies in the Peripheral Nerve Injuries Therapeutics Market include:
Key companies developing therapies for Peripheral Nerve Injuries are – Ono Pharmaceutical, Axogen Corporation, Toyobo, Collagen Matrix, Inc., Integra Life Science, Synovis Micro Companies Alliance, Neuraptive Therapeutics, KlisBio, Orthocell Limited, SaluMedica, and others.
Peripheral Nerve Injuries Pipeline Analysis:
The Peripheral Nerve Injuries pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Nerve Injuries with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Nerve Injuries Treatment.
Peripheral Nerve Injuries key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Peripheral Nerve Injuries Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Nerve Injuries market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Peripheral Nerve Injuries drugs and therapies
Peripheral Nerve Injuries Pipeline Market Drivers
High incidence of nerve injuries, Availability of technologically advanced nerve repair and regeneration products, Research and Development, are some of the important factors that are fueling the Peripheral Nerve Injuries Market.
Peripheral Nerve Injuries Pipeline Market Barriers
However, Delayed and under diagnosis, Lack of epidemiological studies, Limited understanding of the pathophysiology of Peripheral Nerve Injuries and repair, Lack of approved therapies and weak clinical pipeline, and other factors are creating obstacles in the Peripheral Nerve Injuries Market growth.
Scope of Peripheral Nerve Injuries Pipeline Drug Insight
Coverage: Global
Key Peripheral Nerve Injuries Companies: Orthocell, Neuraptive Therapeutics, Samyang Biopharmaceuticals, Astellas Pharma Inc, and others
Key Peripheral Nerve Injuries Therapies: Remplir, NTX-001, CAPNP, QUTENZA, and others
Peripheral Nerve Injuries Therapeutic Assessment: Peripheral Nerve Injuries current marketed and Peripheral Nerve Injuries emerging therapies
Peripheral Nerve Injuries Market Dynamics: Peripheral Nerve Injuries market drivers and Peripheral Nerve Injuries market barriers
Request for Sample PDF Report for Peripheral Nerve Injuries Pipeline Assessment and clinical trials
Table of Contents
1. Peripheral Nerve Injuries Report Introduction
2. Peripheral Nerve Injuries Executive Summary
3. Peripheral Nerve Injuries Overview
4. Peripheral Nerve Injuries- Analytical Perspective In-depth Commercial Assessment
5. Peripheral Nerve Injuries Pipeline Therapeutics
6. Peripheral Nerve Injuries Late Stage Products (Phase II/III)
7. Peripheral Nerve Injuries Mid Stage Products (Phase II)
8. Peripheral Nerve Injuries Early Stage Products (Phase I)
9. Peripheral Nerve Injuries Preclinical Stage Products
10. Peripheral Nerve Injuries Therapeutics Assessment
11. Peripheral Nerve Injuries Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Peripheral Nerve Injuries Key Companies
14. Peripheral Nerve Injuries Key Products
15. Peripheral Nerve Injuries Unmet Needs
16 . Peripheral Nerve Injuries Market Drivers and Barriers
17. Peripheral Nerve Injuries Future Perspectives and Conclusion
18. Peripheral Nerve Injuries Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
